An Absolute Bioavailability Study of LY3314814 in Healthy Subjects Using an Intravenous Tracer Method
Phase of Trial: Phase I
Latest Information Update: 05 Nov 2019
Price : $35 *
At a glance
- Drugs Lanabecestat (Primary) ; Lanabecestat (Primary)
- Indications Alzheimer's disease
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 05 Mar 2018 Status changed from recruiting to completed.
- 19 Jan 2018 Status changed from not yet recruiting to recruiting.
- 04 Dec 2017 Planned End Date changed from 22 Dec 2017 to 1 Feb 2018.